Language selection

Search

Patent 1072543 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1072543
(21) Application Number: 1072543
(54) English Title: CEPHALOSPORIN COMPOUNDS
(54) French Title: COMPOSES DE CEPHALOSPORINE
Status: Term Expired - Post Grant Beyond Limit
Bibliographic Data
(51) International Patent Classification (IPC):
  • C7D 501/36 (2006.01)
  • A61K 31/545 (2006.01)
  • C7D 249/04 (2006.01)
  • C7D 249/12 (2006.01)
  • C7D 257/04 (2006.01)
  • C7D 501/04 (2006.01)
  • C7D 501/06 (2006.01)
  • C7D 501/60 (2006.01)
(72) Inventors :
(73) Owners :
(71) Applicants :
(74) Agent:
(74) Associate agent:
(45) Issued: 1980-02-26
(22) Filed Date:
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data: None

Abstracts

English Abstract


ABSTRACT
The compounds of this invention are cephalosporins
having a thienyl- or tetrazolylacetamido substituent at
the 7-position and a carboxy or carbamoyl substituted
triazolyl- or tetrazolylthiomethyl group at the 3-position
of the cephem nucleus. The compounds have antibacterial
activity.


Claims

Note: Claims are shown in the official language in which they were submitted.


The embodiments of the invention in which
an exclusive property or privilege is claimed are
defined as follows:
1. A process for preparing a compound of
the formula:
<IMG>
in which:
R1 is thienyl or tetrazolyl; and
Het is selected from the group consisting of:
<IMG> ' <IMG> and <IMG>
in which each individual R2 is hydrogen or
lower alkyl, n is zero to ten, m is one to ten and R3
is hydroxy, amino, lower alkylamino or di(lower)alkylamino,
or a non-toxic pharmaceutically acceptable salt thereof,
comprising acylating a compound of the formula:
<IMG>
where Het is defined as above and
R4 is hydrogen or a protecting ester group,
with thienyl or tetrazolyl acetic acid or an activated
-35-

derivative thereof, or reacting a compound of the
formula:
<IMG>
where R1 is defined as above or a salt thereof,
with a compound of the formula:
<IMG> , <IMG> or <IMG>
where R2, R3, n and m are defined as above or
a salt thereof, followed by removal of the protecting
group when necessary, acidifying when necessary and
optionally converting the product to a non-toxic pharmaceuti-
cally acceptable salt.
2. A process as claimed in claim 1 in which
Het is triazolyl.
3. A process as claimed in claim 1 in which
Het is tetrazolyl.
4. A process as claimed in claim 2 in which n
is zero to five, R2 is hydrogen and R3 is hydroxy or amino.
5. A process as claimed in claim 3 in which m
is one to five, R2 is hydrogen and R3 is hydroxy or amino.
6. A process as claimed in claim 3 for preparing
7-(2-thienylacetamido)-3-[1-(10-carbamoyldecyl)tetrazol-5-
ylthiomethyl]-3-cephem-4-carboxylic acid comprising
reacting 7-(2-thienylacetamido)cephalosporanic acid sodium
salt with 1-(10-carbamoyldecyl)tetrazole-5-thiol.
-36-

7. A process as claimed in claim 4 for
preparing 7-(1-tetrazolylacetamido)-3-(5-carboxymethyl-
1,2,4-triazol-3-ylthiomethyl)-3-cephem-4-carboxylic acid
comprising reacting 7-(1-tetrazolylacetamido)cephalo-
sporanic acid with 3-carboxymethyl-1,2,4-triazole-5-thiol
sodium salt and then acidifying.
8. A process as claimed in claim 5 for pre-
paring 7-(2-thienylacetamido)-3-(1-carboxymethyltetrazol-
5-ylthiomethyl)-3-cephem-4-carboxylic acid comprising
acylating 7-amino-3-(1-carboxymethyltetrazol-5-ylthio-
methyl)-3-cephem-4-carboxylic acid with 2-thiophene
acetyl chloride.
9. A process as claimed in claim 5 for pre-
paring 7-(2-thienylacetamido)-3-[1-(2-carbamoylethyl)tet-
razol-5-ylthiomethyl]-3-cephem-4-carboxylic acid comprising
acylating 7-amino-3-[1-(2-carbamoylethyl)tetrazol-5-
ylthiomethyl]-3-cephem-4-carboxylic acid with 2-thio-
phene acetyl chloride.
10. A process as claimed in claim 5 for pre-
paring 7-(1-tetrazolylacetamido)-3-(1-carboxymethyl-
tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid
comprising reacting 7-(1-tetrazolylacetamido)cephalo-
sporanic acid with 1-carboxymethyltetrazole-5-thiol.
11. A process as claimed in claim 5 for pre-
paring 7-(2-thienylacetamido)-3-[1-(2-carboxyethyl)-
tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid
comprising reacting 7-(2-thienylacetamido)cephalosporanic
acid sodium salt with 1-(2-carboxyethyl)tetrazole-5-
thiol then acidifying.
-37-

12. A process as claimed in claim 5 for
preparing 7-(1-tetrazolylacetamido)-3-[1-(2-carboxy-
ethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic
acid comprising reacting 7-(1-tetrazolylacetamido)-
cephalosporanic acid with 1-(2-carboxyethyl)tetrazole-
5-thiol.
13. A compound of the formula:
<IMG>
in which:
R1 is thienyl or tetrazolyl; and
Het is selected from the group consisting of:
<IMG> <IMG> and <IMG>
in which each individual R2 is hydrogen or
lower alkyl, n is zero to ten, m is one to ten and R3
is hydroxy, amino, lower alkylamino or di(lower)alkyl-
amino, or a non-toxic pharmaceutically acceptable salt
thereof, when prepared by the process of claim 1 or its
obvious chemical equivalent.
14. A compound of claim 13 in which Het is
triazolyl, when prepared by the process of claim 2
or its obvious chemical equivalent.
15. A compound of claim 13 in which Het is
tetrazolyl, when prepared by the process of claim 3 or
-38-

its obvious chemical equivalent.
16. A compound of Claim 13 in which Het is triazolyl, n is
zero to five, R is hydrogen and R3 is hydroxy or amino, when prepared
by the process of claim 4 or its obvious chemical equivalent.
17. A compound of claim 13 in which Het is tetrazolyl, m is
one to five, R is hydrogen and R3 is hydroxy or amino, when prepared
by the process of claim 5 or its obvious chemical equivalent.
18. The compound 7-(2-thienylacetamido)-3-[1-(10-
carbamoyldecyl)tetrazol-5-ylthiomethyl]-3-cephem-4-carboxy-
lic acid, when prepared by the process of claim 6 or its
obvious chemical equivalent.
19. The compound 7-(1-tetrazolylacetamido)-3-(5-
carboxymethyl-1,2,4-triazol-3-ylthiomethyl)-3-cephem-4-
carboxylic acid, when prepared by the process of claim 7
or its obvious chemical equivalent.
20. The compound 7-(2-thienylacetamido)-3-(1-
carboxymethyltetrazol-5-ylthiomethyl)-3-cephem-4-car-
boxylic acid, when prepared by the process of claim 8 or
its obvious chemical equivalent.
21. The compound 7-(2-thienylacetamido)-3-[1-(2-
carbamoylethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-car-
boxylic acid, when prepared by the process of claim 9
or its obvious chemical equivalent.
22. The compound 7-(1-tetrazolylacetamido)-3-(1-
carboxymethyltetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic
acid, when prepared by the process of claim 10 or its
obvious chemical equivalent.
- 39 -

23. The compound 7-(2-thienylacetamido)-3-
[1-(2-carboxyethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-
carboxylic acid, when prepared by the process of claim
11 or its obvious chemical equivalent.
24. The compound 7-(1-tetrazolylacetamido)-
3-[1-(2-carboxyethyl)tetrazol-5-ylthiomethyl]-3-cephem-
4-carboxylic acid, when prepared by the process of
claim 12 or its obvious chemical equivalent.
-40-

Description

Note: Descriptions are shown in the official language in which they were submitted.


Sf~3
This invention relates to a new series of cephalo-
sporin compounds which have antibacterial activity when ad-
ministered parenterally. In particular, the compounds of
this invention are characterized by having a carboxy or car-
bamoyl substituted triazolyl or tetrazolylthiomethyl group
; at the 3-position of the cephem nucleus.
The compounds of this invention are represented by
the following structural formula:
'' 10 1 S
R -CH2-CONH
:~ ~ N ~
. O I CH2SHet .
~ COOH
: Formula I
in which:
Rl is thienyl or tetrazolyl; and
. Het is selected from the group consisting of:
^~ \
N_N ~N~
(CHR2)n-CoR3 H (CHR )n-CoR3 ~CHR2) -CoR3
: m
,
. in which each individual R2 is hydrogen or lower alkyl, n is
zero to ten, m is one to ten and R3 is hydroxy, amino, lower
alkylamino or di(lower)alkylamino,
or a non-toxic pharmaceutically acceptable salt thereof.
`- As used herein, the term "lower alkyl" refers to
~ 30 groups having from one to our carbon atoms, especially
:: methyl and ethyl.
,
~ -2-
:'

, ~ ~ zr~
Preferred compounds of this invention are represent-
ed by Formula I in which Het is tetrazolyl substitu~ed with
-(CHR )mCoR3 where R is hydrogen, m is one to -ten and R3
is hydroxy, amino, lower alkylamino or ditlower)alkylamino.
Advantageous compounds of this invention are
represented by Formula I in which Het is tetrazolyl sub-
stituted with -(CHR2) CoR3 where R2 is hydrogen, m is one
to five and R3 is hydroxy or amino.
Particularly preferred are the compounds 7-(2-
thienylacetamido)~3-(1-carboxymethyltetrazol-5-ylthiomethyl)-
3-cephem 4-carboxylic acid, 7-(2-thienylacetamido)-3-[1-
(2-carbamoylethyl)tetrazol-5-ylthiomethyl]-3-cephem-4-car-
. boxylic acid, 7-(1-tetrazolylacetamido)-3-(1-carboxymethyl-
tetrazol-5-ylthiomethyl)-3-cephem-~-carboxylic acid,
7-(2-thienylacetamido)-3 [1-(2-carboxyethyl)tetrazol-5-
ylthiomethyl]-3-cephem-4-carboxylic acid, and 7-(1-tetra-
zolylacetamido?-3-[1-(2-carboxyethyl)tetrazol-5-ylthio-
methyl]-3-cephem-4-carboxylic acid.
Cephalosporin derivatives having a thienylacetamido
or tetrazolylacetamido group at the 7-position are well
documented in the prior art.
Cephalosporins of the present invention, substituted
by a substituted S-heterocyclicthiomethyl group at the 3-
position of the cephem nucleus, are encompassed by a generic
formula in Netherlands Patent 6916151 where Het includes
triazolyl and tetrazolyl optionally substituted with, inter
alia, carboxy, carbalkoxy, alkoxyalkylaminocarbonyl and
` dialkylaminoalkylaminocarbonyl. This formula also contains
. an optionally substituted heterocyclic acetamido group at
the 7-position, among which are included tetrazolylace-tamido
and thienylacetamido. Specifically, only an ester of a
- 3 -

~'7'~
carboxylic acid substituted tetrazolylthiomethyl cephalosporin
; or the present invention is disclosed.
Japanese Patent 7205550 contains a generic formula
for cephalosporin compounds of this invention where Het in-
cludes triazolyl and tetrazolyl substituted with -(CH2)nR3,
where n is 0 to 3 and R3 includes alkoxycarbonyl, carboxy,
N-alkoxyalkylcarbamoyl and dialkylamino and also having a
7-thienylacetamido or 7-tetrazolylacetamido group. Exem-
plified are a 7-tetrazolylacetamido-3-(ester and acid sub-
10- stituted thiadiazolyl)thiomethyl cephalosporin.
Recently issued U.S. Patent 3,819,623 contains a
generic formula for cephalosporins of this invention bearing
a 7-heterocyclicacetamido or 7-heterocyclicthioalkylacetamido
group and having in the 3-position, inter alia, tetrazolyl-
thiomethyl substituted with carboxy, alkoxycarbonyl, carboxy-
alkyl, alkoxycarbonylalkyl and dialkylaminoalkylaminocarbonyl-
alkyl. Among the compounds disclosed are an ester of a com-
pound of this invention, and a carboxylic acid substituted
thiadiazolylthiomethyl analog.
The compounds of Formula I are prepared by acyla-
tion of an appropriate 7-amino-3-substituted triazolyl- or
tetrazolylthiomethyl cephalosporin nucleu~ of Formula II:
' NH2 S
0//~----~ N ~ CH2SHet
COOR
Formula II
in which
, . .
~ 30 ~let is selected from the group consisting of:
,,, ~

H
N N _ N N -N
and ~/ ~
tCHR )n-COR H (CHR )n-COR (CHR )m-COR
in which each individual R2 is hydrogen or lower
alkyl, n is zero to ten, m is one to ten and R3
is hydroxy, amino, lower alkylamino or di(lower)-
alkylamino; and
R is hydrogen or a protecting ester group, with
thienyl or tetrazolyl acetic acid followed by removal of the
protective groups. The carboxylic acid group is activated by
any of the standard methods such as conversion to the mixed
anhydride, acid chloride, acid imidazolide or activated ester.
In addition, a reagent such as dicyclohexylcarbodiimide can
~ be used provided that the carboxyl group on the cephem nucleus
;~ is protected with an easily removable protecting group such
as a benzhydryl, t-butyl, trichloroethyl~ benzyl, benzyloxy-
methyl, p-nitrophenyl, p-methoxyphenyl, p-methoxybenzyl or
p-nitrobenzyl ester.
Alternatively, the compounds of Formula I are pre-
¦ pared by acylating 7-aminocephalosporanic acid with thienyl
or tetrazolyl acetic acid and then displacing the 3-acetoxy
group with the desired substituted triazole or tetrazole thiol.
The protective groups can be removed according to
methods well known to the ar-t, such as with trifluoroacetic
acid when t-bu-tyl protective groups are used. The resulting
salt is converted to the free acid by means of a basic ion
exchange resin such as polystyreneamine ion exchange resin
(Amberlite ~ IR-45) or else by basification of an aqueous solu-
tion of the salt.
_ 5 _
. .

~ .
~V'^~5~3
The thienyl and tetrazoyl acetic acid starting mate-
: rials are known or are prepared by known methods. 7-Thienyl-
acetamidocephalosporanic acid and 7-tetrazolylacetamidocephalo-
sporanic acid are also known (U.S. 3,S16,997).
The 7-amino-3-substituted triazolyl- and tetra-
zolylthiomethyl cephalosporin starting materials of Formula
II are prepared from reaction of 7-aminocephalosporanic acid
` and a substituted triazole or tetrazole thiol.
The substitu-ted 1,2,3-triazole thiols no-t known
` 10 to the art are prepared by rearrangement of a correspondingly
substituted amino thiadiazole according to the procedure
- of Goerdeler and Gnad [Chem. Ber. 99:1618 (1966)], by con-
.~
version of a suitably substituted hydroxy 1,2,3-triazole to
the corresponding thiol by the method of Hoover and Day
[J. Amer. Chem. Soc. 78:5832 (1956)] or by a reaction of an
- acetylene carboxylic acid with a substituted azide and sub-
sequent decarboxylation and thiation.
The substituted tetrazole thiols where R3 is
hydroxy are prepared by reaction of an isothiocyanate, for
example ethyl isothiocyanoacetate, or an N-alkyl dithiocar-
bamate, such as methyl 2-carboxyethyldithiocarbamate, with
an azide such as sodium azide. When R is amino, lower
alkylamino or di(lower)alkylamino, the tetrazole thiols are
prepared from the corresponding tetrazole thiols where R3
is hydroxy by standard methods for the preparation of amides
from acids, for example, by reaction of a tetraæole thiol
where R3 is hydroxy with l,l-carbonyldiimidazole and an
amine of the formula N~R5R6 where R5 and R6 are each hydrogen
or lower alkyl, or by conversion of the -tetrazole -thiol where
; 3
R is hydroxy to the corresponding acid chloride with sub-
sequent reac-tion of the acid chloride with an amine (NHR5R ).
.,
- 6 -

The tetrazole thiols are also prepared by conversion of a
sui-tably substituted hydroxy tetrazole to the corresponding
thiol by the method of Hoover and Day [J. Amer. Chem. Soc.
78:5~32 (lg56)].
The compounds of this invention are capable of
forming salts with, for example, the alkali metals such as
sodium or potassium, the alkaline earth metals such as calcium
or with the ammonium cation. These salts are prepared by
standard methods using a wide variety of non-toxic pharmaceu-
tically acceptable acids and bases known in the art and are
also considered as objects of this invention.
It will be recognized that due to the potentially
asymmetric carbon atom in the 3-heterocyclic side chain of
Formula I, optical isomers may exist. Racemic or resolved
products are obtained depending upon whether a racemic or
resolved side chain acid is used as an acylating agent. The
resolved side chain acids are readily obtained from the
racemic compounds by resolution according to well known methods,
including fractional crystallization of a salt formed with an
optically active base. All of the isomers, including separated
isomers and mixtures thereof, are included within the scope
of this invention.
The compounds of Formula I have antibacterial acti-
vity against both Gram-positive and Gram-negative organisrns.
They also exhibit high serum leve:Ls and serum half-life values.
Minimum inhibitory concentrations (MIC's) ranged from 0.2 to
~200 ~g./ml. in in vitro testing. These results are shown in
Table 1 below for a number of compounds of Formula I. In vivo
mouse protection data are given in Table 2. Compound names
corresponding to numbers are given in Table 3.

5~3
. . . ~ .
~ ~ o o~9 o o oIn oo Lr~ o
o o o n ~ oo ~ o
~, ~ ~,
A A A
::
~D ~ ~ O O O ~ O O O ~ O~D 0 ~1 0
O O O O O
~1~I t~l ~ t`l
A A
U~ ~~D O O ~ ~ ~ r~ O~9 ~O O ~ O
O O ~1 0 00 ~1 0
. A A A
~ ~ ~ 00 ~~9 ~ ~ ~ Ln ~
_ ~ ~OOO~OOO~O~O
O O 0 ~10 0
~1 A A A
.,
~ I
., ~1
1':1 H~ ~J O ~1 ~J O
:' ~ ~ ~ ~
~3 A A
. ~ ~ ~ ~ CO ~ ~ 0~ 0CO
. ........ o
O O ~ ~ O ~~1 0 ~`IO O '10 ~1 0
.~ . ` ` ` ` ` ` ` ` A ` ` Ll-) ` O
. ~r ~ ~u~ ~9 ~~D CO ~~t'
., t~l
.,................ O O O ~ ~ ~ ~ O OO O O O ~9 0
., ~ O ~ O
N ~I
r--l CO r--l~r) r-l ~ CO~I r-l
~1 ~ O O O ~ D ~ O O O ~ In o ~ o
. InIn O ~ O
A A
,
. CO
,.
CO OO U~
~,~ Ll~) ~CO ~I
.' ~ O O ~ ~0~ ~1
. ~ o o 1--
., ~ ~ ~ ~1
O ~r--I ~1 0 51 1~
.,`~a~ ~ ~ ~r--l ~_) m r--l
., ~) X ~; r-l ~1 ~ O O 1~ 0 1
O ~ U~ N~a E3 .~ P:l ~10 ~_1
~ ~t) ~ m ~ h r-l O
~ r-l
tl) a)~J4-1 r~ r~
S I hr~ l r-l O ~--1 0~ O
O O ra Oa) hn~
a) a) ~~i~rl ~~1 ~J O
-- 8

JZ~'~3
TABLE 2
ED in vlvo (mg./kg.)
Compound E. coli 12140 ~leb. pneumo. 4200
, :,
s.c. p.o. s.c. p.o.
\
1 21.. ~ - 3.9 ~
. 2 1.56 46 1.56 35
3 7.2 35 1.0 40
4 0.4 >50 1.8 >50
5 21.2 ---- 25 -~--
6 1.12 >50 1.56 -~
7 -___ ____
TABLE 3
.
; Compound Number Compound Name
1 7-(2-thienylacetamido)-3-(1-carboxy-
methyltetrazol-5-ylthiomethyl)-3-
cephem-4-carboxylic acid
.~ 2 7-(2-thienylacetamido)-3-[1-(2-
carbamoylethyl)tetrazol-5-ylthio
~: 20 methyl]-3-cephem-4-carboxylic acid
3 7-(2-thienylacetamido)-3-[1-(2-
carboxyethyl)tetrazol-5-ylthiomethyl]-
3-cephem-4-carboxylic acid
4 7-(1-tetrazolylacetamido)-3-(1
carboxymethyltetrazol-5-ylthiomethyl)-
3-cephem-4-carboxylic acid
7~ tetrazolylacetamido)-3-(5-carboxy- -.
methyl-1,2,4-triazol-3-ylthiomethyl)-
3-cephem-4-carboxylic acid
: 30 6 7-(1-tetrazolylacetamido)-3-[1-(2-
carboxyethyl)tetrazol-5-ylthiomethyl]-
3-cephem-4-carboxylic acid
7 7-(2-thienylacetamido)-3-[1-(10-
.:- carbamoyldecyl)tetrazol-5-ylthiomethyl]-
: 3-cephem-4-carboxylic acid
Pharmaceutical compositions having antibacterial
activity which comprise a pharmaceutical carrier and a
compound of Formula I and methods of treating or preventing
.: bacterial infections by admi.nistering a compound of

Formula I to an animal in a nontoxic amount sufficiènt to
treat or prevent said infection are also objects of -this
invention. The administration may be by parenteral in-
jection such as subcutaneously, intramuscularly or intra- -
venously. The injection of suitably prepared sterile solu-
tions or suspensions containing an effective, nontoxic amount
of the new cephalosporin compound is the preferred route of
administration.
The compounds of Formula I are formulated and
administered in the same manner as other cephalosporins in
dosages of from 250 to 1000 mg. with the total daily dosage
being from 1 to 6 g. The precise dosages are dependent upon
the age and weight of the subject and on the infection being
treated and can be determined by those skilled in the art
- based on the data disclosed herein compared with that available
to the art attained with known cephalosporins.
The following examples illustrate the invention,
but are not to be construed as limiting the scope thereof.
- Temperatures are in degrees Centrigrade unless otherwise
stated.
EXAMPLE 1
7-(1-Tetrazolylacetamido)-3-(5-carboxymethyl-1,2,4-triazol-
3-ylthiomethyl)-3-cephem-4-carboxylic acid
To a solution of 1.05 g. (12.5 mmol.) of sodium
bicarbonate in 30 ml. of water was added 1.36 g. (7.5 mmol.)
of 3~carboxymethyl-1,2,4-triaæol-5-thiol sodium salt, pre-
pared by addition of one equivalent of a sodium hydroxide
solution to a solution of 3-carboxymethyl-1,2,4--triazol-5-
thiol in aqueous ethanol, and 1.91 g. (5.0 mmol~) of 7-
(l-tetrazolylacetamido)cephalosporanic acid. The reaction
mixture was heated at 67.5 for four hours while maintaining
- 10 -

~ 5~
the pH a-t 7.6 by addition of glacial acetic acid. The mixture
was cooled to 20, acid was added to bring the pH to 3.5 and
the resulting solution was lyophilized and the residue trit-
urated with ethanol. The product was dissolved in 15 ml. of
absolute methanol and 0.196N solution of sodium methoxide in
methanol was added until ca. pH 6Ø Ethyl acetate was then
added to the solution and the precipitate was collected and
dried in vacuo to give 7-(1-tetrazolylacetamido)-3-(5-carboxy-
methyl-1,2,4-triazol-3-ylthiomethyl)-3-cephem-4-carboxylic
acid disodium salt.
H N O S 2 Na 3 5 H O
Calculated: 31.98% C; 3.74gO H; 21.18% N; 10.54% S
Found: 32.53% C; 3.14% H; 20.72% N; 10.55% S
7-(1-Tetrazolylacetamido)-3-(5-carboxymethyl-
1,2,4-triazol-3-ylthiomethyl)-3-cephem-4-carboxylic acid
; disodium salt is dissolved in a minimum amount of water
to which ethyl acetate is added. While stirring, 3N hydro
chloric acid is added until the solution is acidified to
pH 2.5. The layers are separated, the aqueous phase is
extracted with ethyl acetate and the combined extracts
are washed with water, dried (MgSO4) and evaporated to
dryness to give the title compound.
EXAMPLE 2
7-(2-Thienylacetamido)-3-(5-carboxymethyl-1,2,4-triazol-3-
ylthiomethyl)-3-cephem-4-carboxylic acid
When an equivalent amount of 7-(2-thienylacetamido)-
cephalosporanic acid is substituted in the procedure of Example
; 1 for 7-(1-tetrazolylacetamido)-cephalosporanic acid~ the
title compound is obtained.
The title compound may be converted to the corres-
ponding disodium salt by addition of sodium methoxide solution
as described in Example 1
' ~

EXAMPLE 3
7~ Tetrazolylacetamido)-3-(4-carboxy-1,2,3-triazol-5-
ylthiomethyl)-3-cephem-4-carboxylic acid
_
To a solution of 4.6 g. (0.20 mol.) of sodium and
250 ml. of absolute ethanol was added under a nitrogen atmo-
sphere 8.65 g. (0.05 mol.) of 5-amino-4-carbethoxy-1,2,3-
thiadiazole. The reaction mixture was stirred one hour, 5
ml. of water was added and the mixture was refluxed for 12
hours. After cooling, the mixture was filtered and the solid
product was washed with ethanol and ether and dried to give
4-carboxy-1,2,3-triazole-5-thiol trisodium salt.
Acidification of an aqueous solution of 4-carboxy-
1,2,3-triazole-5-thiol trisodium salt gives 4-carboxy-1,2,3-
triazole-5-thiol. The corresponding mono-sodium salt is
prepared as described in the procedure of Example 1.
Substitution of an equivalent amount of 4-
- carboxy-1,2,3-triazole-5-thiol sodium salt in the procedure
of Example 1 for 3-carboxymethyl-1,2,4-triazole-5-thiol
sodium salt gives the ti-tle compound.
` 20 EXAMPLE 4
7-(1-Tetrazolylacetamido)-3-(4-carbamoyl-1,2,3-triazol-5-
ylthiomethyl)-3-cephem-4-carboxylic acid
. . . _
Reaction of 7-(1-tetrazolylacetamido)cephalo-
sporanic acid, 4-carbamoyl-1,2,3-triazole-5-thiol sodium
salt, prepared from 4-carbamoyl-1,2,3-triazole-5-thiol
as described above, and sodium bicarbonate according to
the procedure of Example 1 gives the title compound.
EXAMPLE 5
7~ Tetrazolylacetamido)-3-[4-(2-carboxyethyl)-1,2,3-
~ 30 triazol-5-yl-thiomethyl]-3-cephem-4-carboxylic acid
- To a solu-tion of 1.725 g. (75 mmol.) of sodium
- - 12 -

- in 50 ml. of absolute ethanol was added 6.0 g. (45 mmol.)
of benzylazide and 12.3 g. (50 mmol.) of diethyl 2-(carbo-
methoxyethyl)malonate. The reaction mixture was refluxed
for 12 hours, then cooled and evaporated to dryness. Water
(100 ml.) was added and the mixture was heated while main-
taining the pH at 12. The aqueous mixture was extracted with
ethyl acetate and the aqueous phase was acidified with 3N
hydrochloric acid and extracted with ethyl acetate. The ethyl
acetate solution was evaporated to dryness to give l-benzyl-
4-(2-carboxyethyl)-5-hydroxy-1,2,3-triazole.
l-Benzyl-4-(2-carboxyethyl)-5-hydroxy-1,2,3-triazole
(5.0 g., 0.02 mol~) was suspended in 300 ml. of ethanol. An-
hydrous hydrogen chloride gas was bubbled in-to the suspension
for 30 minutes and the mixture was then heated on a steam
bath for 20 minutes. The solution was cooled and evaporated
! to dryness to give a residue which was dissolved in 300 ml.
of ethyl acetate. The ethyl acetate solution was washed with
water, dried (~gSO4) and evaporated to dryness. Trituration
with hexane containing a little acetone gave l-benzyl-4-(2-
carbethoxyethyl)-5-hydroxy-1,2,3-triazole.
A solution of 0.63 g. (2.3 mmol.) of 1-benzyl-4-
(2-carbethoxyethyl)-5-hydroxy-1,2,3-triazole in 0.70 g.
(3.5 mmol.) of phenylphosphonic dichloride was heated under
~` a nitrogen atmosphere a-t 160 for 1.5 hours. Water (2 ml.)
and 2 ml. of chloroform were added -to the reaction mixture
and it was stirred at 5 while 6 ml. of 5~ aqueous sodium
bicarbonate was added. The mixture was extracted with
chloroform and the extract was dried (Na2SO4) and evaporated
to dryness to give 1-benzyl-4~(2-carbethoxyethyl)-5-chloro-
1,2,3-triazole.
A solution of 0.54 g. (0.01 mol.) of sodium
::
- 13 -
' .


me-thoxide in 50 ml. of absolute ethanol is saturated with
hydrogen sulfide. l-Benzyl-4-(2-carbethoxyethyl)-5-chloro-
1,2,3-triazole (2.9 g., 0.01 mol.) is added and the reaction
mixture is refluxed for 24 hours. The cooled mixture is
evaporated to dryness to give l-benzyl-4-(2-carboxyethyl)-
1,2,3-triazole-5-thiol sodium salt. Acidification of an
aqueous solution of the triazole thiol salt as previously
described gives l-benzyl-4-(2-carboxyethyl)-1,2,3-triazole-
5-thiol.
1-Benzyl-4-(2-carboxyethyl)-1,2,3-triazole-5-
thiol (1.1 g., 4 mmol.) is suspended in 50 ml. of anhydrous
liquid ammonia and sodium is added until a permanent blue
color results. The reac-tion mixture is allowed -to stir for
40 minutes then allowed to warm to ambient tempera-ture while
the ammonia evaporates. The residue is triturated with ether
and the solid formed is collected and dissolved in water.
The aqueous solution is acidified and extracted with ethyl
acetate. The extract is dried (MgSO4) and evaporated to
dryness to give 4-(2-carboxyethyl)-1,2,3-triazol-5-thiol.
The corresponding sodium salt is prepared as described in
Example 1.
Substitution of 4-(2-carboxyethyl)-1,2,3-triazole-
5-thiol sodium salt in the procedure of Example 1 for 3-
carboxymethyl-1,2,4-triazole-5-thiol sodium salt gives the
title compound.
EXAMPLE 6
: Use of equivalent amounts of diethyl 2-carbethoxy-
methylmalonate and diethyl 2-(carbethoxypropyl)malonate/
respectively, in the procedure of Example 5 in place of di-
ethyl 2 (carbomethoxyethyl)malonate, followed by the steps
` of ester hydrolysis, chlorination, sulfide displacement and
'''
~ - 14 -
.

debenzylation described therein gives 4-carboxymethyl-1,2,3-
triazole-5-thiol and 4-(3-carboxypropyl)-1,2,3-triazole-5-
thiol. The corresponding sodium salts are prepared as des-
cribed in the procedure of Example 1.
Use of 4-carboxymethyl-1,2,3-triazole-5-thiol sodium
salt and 4-(3-carboxypropyl)-1,2,3-triazole-5-thiol sodium
salt in the procedure of Example 1 in place of 3-carboxymethyl-
1,2,4-triazole-5-thiol sodium salt gives, respectively, 7-
(l-tetrazolylacetamido)-3-(4-carboxymethyl-1,2,3-triazole-
5-ylthiomethyl)-3-cephem-4-carboxylic acid and 7-(1-tetra-
zolylacetamido)-3-[4-(3-carboxypropyl)-1,2,3-triazol-5-
ylthiomethyl]-3-cephem-4-carboxylic acid.
EXAMPLE 7
To a solution of 13.8 g. (0.6 mol.) of sodium
in absolute ethanol is added a solution of 96 g. (0.6 mol.)
of diethylmalonate in 500 ml. of ether. The mixture is
cooled and 117.1 g. (0.6 mol.) of 2-bromo-2-methylpropionic
acid ethyl ester is added. The reaction mixture is warmed
for two hours, then stirred at ambient temperature for 48
hours. Acetic acid and water are added, the layers are
separated and the ethereal phase is washed with water, dried
(MgSO4) and evaporated to dryness to give diethyl 2-(1-
carbethoxy-l-methylethyl)malonate.
When an equivalent amount of the following bromo-
esters:
3-bromo-2,2-dimethylpropionic acid
methyl ester
5-bromo-2-methylvaleric acid methyl
ester
2-bromo-2-ethylbutyric acid methyl
ester

: is used in place of 2-bromo-2-methylpropionic acid e-thyl
ester in the reaction with diethylmalonate, the substituted
malonates listed below are obtained:
diethyl 2-(2-carbomethoxy-2-methylpropyl)-
malonate
diethyl 2-(4-carbomethoxypentyl)malonate
~ diethyl 2-(1-carbomethoxy-1-ethylpropyl)malonateO
: Substitution of a substituted malonate named
hereinabove in place of diethyl 2-(carbomethoxyethyl)malonate,
as a starting material in the p~ocedure of Example 5 followed
by the subsequent syn~hetic steps described therein, gives
the following triazole thiols as products:
4-(l-carboxy-l-methylethyl)-1,2,3-triazole-5-
thiol
4-(2-carboxy-2-methylpropyl)-1,2,3-triazole-5-
thiol
4-(4-carboxypentyl)-1,2,3-triazole-5-thiol
4-(1-carboxy-l-ethylpropyl)-1,2,3-triazole-5-
thiol.
Use of a substituted triazole thiol sodium salt,
prepared as described above, in the procedure of Example l
in place of 3-carboxymethyl-1,2,4-triazole-5-thiol sodium
salt gives the following 7-(l-tetrazolylacetamido)-3-(sub-
stituted triazolyl)thiomethyl cephalosporin compounds:
. 7-(l-tetrazolylacetamido)-3-[4-
.. (l-carboxy-l-methylethyl)-1,2,3-triazol-5-
ylthiomethyl]-3-cephem-4-carboxyli.c acid
; 7-(1-tetrazolylacetamido)-3-[4-(2-
carboxy-2-methylpropyl)-1,2,3-triazol-5-
ylthiomethyl]-3-cephem-4-carboxylic acid
- 16 -

~0~s~
7-(1-tetrazolylacetamido)-3-[4-(4-
carboxypentyl)-1,2,3-triazol-5-ylthiomethyl]-3
cephem-4-carboxylic acid
7-(1-tetrazolylacetamido)-3-~4-(1-
carboxy 1-ethylpropyl)-1,2,3-triazol-5-ylthio-
; methyl]-3-cephem-4-carboxylic acid.
; EXAMPLE 8
7-(1-Tetrazolylacetamido)-3-(4-N-methylcarbamoyl-1,2,3-
triazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid
A solution of 7.2 g. (44 mmol.) of l,l-carbonyl-
diimidazole in 110 ml. of dry tetrahydrofuran and 20 ml. of
dimethylformamide is added to a solution of 7.7 g. (43.8 mmol.)
of 4-carboxy-1,2,3-triazol-5-thiol in 110 ml. of ary tetra-
; hydrofuran and 20 ml. of dimethylformamide. Tetrahydrofuran
saturated with methylamine is added and the reaction mixture
` is stirred at 25 for 12 hours. The mixture is evaporated
~ to dryness, the residue is diluted with 200 ml. of water and
; the resulting solution is adjusted to pH 2-3 by addition of
sulfuric acid. The aqueous solution is lyophilized and the
residue extracted with acetone to give 4-N-methylcarbamoyl-
1,2,3-triazole-5-thiol.
Reaction of 4-N-methylcarbamoyl-1,2,3-triazole-5-
~- thiol sodium salt, prepared as described above, with 7-(1-
tetrazolylacetamido)cephalosporanic acid as described in the
procedure of Example 1 gives the title compound.
EXAMPLE 9
When ethylamine, propylamine or butylamine is sub-
stituted for methylamine in the procedure of Example 8, the
. .,
following triazole thiols are prepared:
....
~ 30 4-N-ethylcarbamoyl-1,2,3-triaæole-5-thiol
,,'
4-N-propylcarbamoyl-1,2,3-triazole-5-thiol
4-N-butylcarbamoyl-1,2,3-txiazole-5-thiol
'' .
- 17 -
:
:, . .
.~ .
"' "' ' '
"

1~)7Z~3
Reaction of the sodium salt of a triazole thiol
listed above, prepared as described in Example 1, with
7~ tetrazolylacetamido)cephalosporanic acid or 7-(2-
thienylacetamido)cephalosporanic acid as described herein-
above, gives the following compounds of this invention:
7-(l-tetrazolylacetamido)-3-(4-N-
ethylcarbamoyl-1,2,3-triazol-5-ylthiomethyl)-3-
cephem-4-carboxylic acid
7-(1-tetrazolylacetamido)-3-(4-N-
propylcarbamoyl-1,2,3-triazol-5-ylthiomethyl)-3-
cephem-4-carboxylic acid
7-(1-tetrazolylacetamido)-3-(4-N-
butylcarbamoyl-1,2,3-triazol-5-ylthiomethyl)-3-
cephem-4-carboxylic acid
7-(2-thienylacetamido)-3-(4-N-ethyl-
carbamoyl-1,2,3-triazol-5-ylthiomethyl)-3-
cephem-4-carboxylic acid
7-(2-thienylacetamido)-3-(4-N-propyl-
carbamoyl-1,2,3-triazol-5-ylthiomethyl)-3-
; 20 cephem-4-carboxylic acid
7-(2-thienylacetamido)-3-(4 N butyl-
carbamoyl-1,2,3-triazol-5-ylthiomethyl)-3-
cephem-4-carboxylic acid
E~AMPLE lO
7-(1-Tetrazolylacetamido)-3-(5-N,N-dimethylcarbamoylmethyl
- 1,2,4-triazol-3-ylthiomethyl)-3-cephem-4-carboxylic acid
To a solution of 5.34 g~ (33.8 mmol.) of 3-
carboxymethyl-1,2,4~triazole-5-thiol in 75 ml. of dry
tetrahydrofurarl and 20 ml. of dry dimethylformamide is
slowly added a solution of 5.49 g. (33.9 mmol.) of 1,1-
carbonyldiimidazole in 95 ml. of dry dimethylformamide.
-'
-- 18 --
. , . , . . , ' .
.,

!
~ 3
The reaction mixture is stirred for 35 minutes, then 250 ml.
of tetrahydrofuran saturated with dimethylamine is added to
the suspension and it is stirred at 25 for 12 hours. The
mixture is concentrated to about 200 ml. and tetrahydrofuran
and ether are added. The precipitate is collected by filtra-
tion and dissolved in 170 ml. of water. The aqueous solution
is acidified to pH 2.0 by addition of 6N sulfuric acid and
extracted with ethyl acetate. The ethyl acetate solution is
- evaporated to dryness and triturated with ether to give 3-N,
N-dimethylcarbamoylmethyl-1,2,4-triazole-5-thiol.
Reaction of 3-N,N-dimethylcarbamoylmethyl-1,2,4-
triazole-5-thiol sodium salt, prepared as described in
`~ Example 1, with 7-(1-tetrazolylacetamido)cephalosporanic acid
as described therein gives the title compound.
E ~ ~LE 11
When diethylamine, dipropylamine or dibutylamine
is substituted for dimethylamine in the procedure of Example
10, the following triazole thiols are prepared:
3-N,N-diethylcarbamoylmethyl-1,2,4-triazole-5-
thiol
3 N,N dipropylcarbamoylmethyl-1,2,4-triazole-5-
thiol
3-N,N-dibutylcarbamoylmethyl-1,2,4-triazol-5-
thiol
Reaction of the sodium salt of a triazole thiol
listed above, prepared as described in Example 1, with
. 7-tl-tetrazolylacetamido)cephalosporanic acid or 7-(2-
thienylacetamiao)cephalsoporanic acid as described above
.,
gives the following compounds of this invention, respectively:
`~^
'
." -- 19 --
.. ", ' ' ' .
,' ' '

1 l)~2Sf~3
7-(1-tetrazolylacetamido)-3-(5-N,N-
diethylcarbamoylmethyl-1,2,4-triazol-3-ylthio-
methyl)-3-cephem-4-carboxylic acid
7-(1-tetrazolylacetamido)-3-(5-N,N-
dipropylcarbamoylmethyl-1,2,4-triazol-3-
ylthiomethyl)-3-cephem-4-carboxylic acid
7-(1-tetrazolylacetamido)-3-(5-N,N-
dibutylcarbamoylmethyl-1,2,4-triazol-3-ylthio-
methyl)-3-cephem-4-carboxylic acid
7-(2-thienylacetamido)-3-(5-N,N-
diethylcarbamoylmethyl-1,2,4-triazol-3-ylthio-
methyl)-3-cephem-4-carboxylic acid
7-(2-thienylacetamido)-3-(5-N,N-
dipropylcarbamoylmethyl-1,2,4-triazol-3-
ylthiomethyl)-3-cephem-4-carboxylic acid
7-(2-thienylacetamido)-3-(5-N,N-
dibutylcarbamoylmethyl-1,2,4-triazol-3-ylthio-
methyl)-3-cephem-4-carboxylic acid.
EXAMPLE 12
7-(2 Thienylacetamido?-3-(1-carboxymethyltetrazol-5-ylthio-
methyl?-3-cephem-4-carboxylic acid
Glycine (60 g., 0.8 mol.) was added to a cooled
(5-10) solution of 89.6 g. (1.6 mol.) of po-tassium hydroxide
in 200 ml. of water. After complete dissolution 60.8 g.
; (0.8 mol.) of carbon disulfide was added and the reaction
mixture was stirred at 25 for three hours. A solution of
113.6 g. (0.8 mol.) of methyl iodide in 200 ml. of ethanol
was added while malntaining the temperature at 25-30~. The
reaction mixture was stirred for two hours a-t 25, then con-
centrated in vacuo and the remaining aqueous phase was made
basic (pH 8.0) with aqueous sodium carbona-te and extrac-ted
t - 20 -
'

~ ~U~7~
with ether. The aqueous phase was acidified to pH 2.5 with
dilute hydrochloric acid and extracted with ethyl acetate.
The extract was concentrated in vacuo and the residue re~
crystallized from toluene to give methyl carboxymethyldithio-
carbamate.
A mixture of 16.5 g. (0.1 mol.) of methyl carboxy-
methyldithiocarbamate and 14.3 g. (0.22 mol.) of sodium azide
in 150 ml. of water was heated at 56 for 12 hours. The
; reaction mixture was extracted with ether, then acidified to
pH 1.5 with dilute hydrochloric acid and ex-tracted with e-thyl
acetate. The extract was dried (MgSO4) and evaporated to
dryness to give l-carboxymethyltetrazole-5-thiol, m.p. 178-
179.
l-Carboxymethyltetrazole-5-thiol was also prepared
by refluxing a mixture of 45.95 g. (0.316 mol.) of ethyl
isothiocyanoacetate and 30.8 g. (0.475 mol.) of sodium azide
in 500 ml. of water for 2.75 hours. Ethyl acetate (400 ml.)
was added to the cooled reaction mixture and it was acidified
to pH 1.9 with 3N hydrochloric acid. The layers were separated,
~- 20 the aqueous phase was extracted three times with ethyl acetate
and the combined extracts were dried (MgSO4) and evaporated
to dryness to give a residue which was chromatographed on
silica gel with 17:3:2 chloro-form-isopropanol-formic acid to
` give the tetrazole thiol.
A mixture of 2.94 g. (10 mmol.) of 7-aminocephalo-
; sporanic acid sodium salt, 2.40 g. (15 mmol.) of 1-carboxy-
methyltetrazole-5-thiol and 2.52 g. (30 mmol.) of sodium
bicarbonate in 40 ml. of water was heated at 70 for four
hours. The reaction mixture was cooled (ice bath), acidified
to pH 1.8 with 3N hydrochl~ric acid and evaporated to dryness
in vacuo to give 7-amino-3-(1-carboxymethytetrazol-5-ylthio-
,.
~ 21 -
.:

~ 3
methyl)-3-cephem-4-carboxylic acid.
To a solution of 1.86 g. (5 mmol.) of 7-amino-3-
(l-carboxymethyltetrazol-S-ylthiomethyl)-3-cephem-4-carboxylic
acid and 1.68 g. (0.02 mol.l of sodium bicarbonate in 60 ml.
of water and 50 ml. of acetone at -15 was added a solution
of 0.80 g. (5 mmol.) of 2-thiophene acetyl chlorlde in 50 ml.
of acetone. The reaction mixture was stirred and the tempera-
ture maintained below -10 during addition. The mixture was
stirred for 3.5 hours, then the acetone was removed ln vacuo
and the~aqueous residue was extracted with ethyl acetate.
Ethyl acetate was added to the aqueous phase and it was
acidified to pH 1.5 by addition of 3N hydrochloric acid. The
layers were separated and the aqueous phase was extracted with
ethyl acetate. The extract was dried (MgSO4) and evaporated
i to dryness to give a residue, which was chromatographed on
silica with 8:2:1 chloroform-isopropanol-acetic acid as
- eluent. The product was dissolved in ethyl acetate and
triturated with hexane to give the title compound.
C17H16N6O6S3 0.25 C4 8 2
Calculated: 41.69% C; 3.49% H; 16.20% N
Found: 41.51% C; 3.54% H; 15.74% N
~ The title compound is dissolved in methanol and the
; methanol solution is treated with 0.196N sodium methoxide in
methanol. The methanol is removed in vacuo and the residue
.- .
is dissolved in a minimum amount of water to which isopropanol
; is added to give 7-(2-thienylacetamido)-3-(1-carboxymethyl-
tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid sodium
salt.
EXAMPLE 13
30 7-(2-Thienylacetamido)-3-(1-N-methylcarbamoylmethyltetrazol-
.
5-ylthiomethyl)-3 cephem-4-carboxylic acid
. ~
A solution of 7.2 g. (44 mmol.) of l,l-carbonyl-
- 22 -

~'7~
diimidazole in 110 ml. of dry tetrahydrofuran and 20 ml. of
dimethylformamide was added to a solution of 7.0 g. (43.8 mmol.)
of l-carboxymethyltetrazole-5-thiol in 110 ml. of dry tetrahydro-
furan and 20 ml. of dimethylformamide. Tetrahydrofuran saturated
with methylamine was added and the reaction mixture was stirred
at 25 for 12 hours. The mixture was evaporated to dryness ln
vacuo, the residue was diluted with 200 ml. of water and the
resulting solution was adjusted to pH 2-3 by addition of 3N
hydrochloric acid. The aqueous solution was extracted with ethyl
acetate and the extract was dried (MgSO4) and evaporated to dry-
ness. Ethyl acetate (15 ml.) and ether (10 ml.) were added to
the residue and it was cooled to induce crystallization of l-N-
methylcarbamoylmethyltetrazole-5-thiol, m.p. 137-140.
Reaction of l-N-methylcarbamoylmethyltetrazole-5-thiol,
7-aminocephalosporanic acid sodium salt and sodium bicarbonate as
described in the procedure of Example 12 gives 7-amino-3-(1-N-
~` methylcarbamoylmethyl-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxy-
lic acid.
Substitution of 7-amino-3-(1-N-methylcarbamoylmethyl-
tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid in -the pro-
cedure of Example 12 for 7-amino-3-(1-carboxymethyltetrazol-5-
ylthiomethyl)-3-cephem-4-carboxylic acid while maintaining the
pH at 7~6 - 7.8 throughout the reaction by addi-tion of solid
sodium bicarbonate gives the title compound.
: EX~MPLE 14
7-(2-Thienylacetamido)-3-(1-N,N-dimethylcarbamoylmethyltetrazol-
5-ylthiomethyl)-3-cephem-4-carboxylic acid
To a solution of 5.42 g. (33.8 mmol.) of l-carboxymethyl-
tetrazole-5-thiol in 75 ml. of dry tetrahydrofuran and 20 ml. of
dry dimethylformamide was s:Lowly added a solution of 5.49 g.
(33.9 mmol.) of l,l-carbonyldiimidazole in 95 ml. of dry dimethyl-
formamide. The reaction mixture was stirred for 35 minutes, then
~ 23 -

250 ml. of tetrahydrofuran saturated with dimethylamine was
added to the suspension and it was stirred at 25 for
12 hours. The mixture was concentrated to about
- 23a -

:~a3';'2~43
200 ml. and tetrahydrofuran and ether were added. The pre-
cipitate was collected by filtration and dissolved in 170 ml.
of water. The aqueous solution was acidified to pH 2.0 by
addition of 6N sulfuric acid and extracted with ethyl acetate.
The ethyl acetate solution was evaporated to dryness and the
residue was triturated with ether to give l-N,N-dimethyl-
carbamoylmethyltetrazole-5-thiol, m.p. 190-200 (dec.).
Reaction of l-N,N-dimethylcarbamoylmethyltetrazole-
5-thiol with 7-aminocephalosporanic acid sodium salt as
described in Example 13 followed by reaction of the 7-amino-
3-(1-N,N-dimethylcarbamoylmethyltetrazol-5-ylthiomethyl)-3-
cephem-4-carboxylic acid thus formed with 2--thiophene acetyl
chloride as described in Example 12 gives the title compound.
EXAMPLE 15
~,- 7-(2-Thienylacetamido3-3-(1-carbamoylmethyltetrazol-5-
ylthiomethyl)-3-cephem-4-carboxylic acid
l-Carboxymethyltetrazole-5-thiol and l,l-carbonyl-
diimidazole were reacted as described in Example 13. To the
reaction mixture was added tetrahydrofuran saturated with
; 20 dry ammonia gas. The resulting suspension was stirred for 2.5
hours and the solid which formed was collec-ted by filtration,
washed with tetrahydrofuran and dissolved in methanol.
Amberlite IR-120 ion-exchange resin (50 g.) was added and
the suspension was stirred for 15 minutes. The resin was then
- removed and washed with absolute methanol. The methanol solu-
tion was evaporated to dryness to give l-carbamoylmethyltetra-
zole-5-thiol, m.p. 200 (dec.).
l-Carbamoylmethyltetrazole-5-thiol is reacted with
7-aminocephalosporanic acid sodium salt to give 7-amino-3-
(1-carbamoylmethyltetrazol-5-ylthiomethyl)-3-cephem~4-carboxy-
. . .
lic acid, which upon reaction with 2 thiophene acetyl chloride
as described in Example 12, gives -the -ti-tle compound.
- 24 -
'
.', ~

~'7~5'~
~EXAMPLE 16
7-(2-Thienylacetamido)-3-[1-(2-carboxyethyl)tetrazol-5-
ylthiomethy-1]-3-cephem-4-carboXy-lic acid
3-Alanine (17.8 g., 0.2 mol.) was added to a solu-
tion of 22.4 g. (0.4 mol.) of potassium hydroxide in 500 ml.
of water at 25. Carbon disulfide (12.2 ml., 0.2 mol.) was
added and the reaction mixture was refluxed for three hours.
The mixture was cooled, 28.4 g. (0.2 mol.) of methyl iodide
and 500 ml. of ethanol were added and the resulting mixture
was stirred for 30 minutes. The precipitate was collected by
filtration, the filtrate was cancen-trated and the aqueous
residue was combined with the solid material and brought to
pH 8.5-9 by addition of 10% aqueous sodium hydroxide. The
resulting suspension was extracted with ethyl acetate and
the extract discarded. Ethyl acetate was added to the aqueous
phase which was then acidified to pH 1.5 with 6N hydrochloric
acid. The layers were separated and the aqueous phase was
extracted with ethyl acetate. The ethyl acetate extracts
were combined, dried (MgSO4) and evaporated to dryness to give
methyl 2-carboxyethyldithiocarbamate.
To a mixture of 25.37 g. (0.143 mol.) of methyl
2-carboxyethyldithiocarbamate and 5.6 g. (0.143 mol.) of
sodium hydroxide in 210 ml. of water was added 9.25 g.
- (0.143 mol.) of sodium azide. The reaction mixture was re-
- fluxed for one hour then cooled, 100 ml. of ether was added
; and the mix-ture was acidified to pH 1.7O The layers were
separated, the aqueous phase was extracted with ether and
the combined extracts were dried (MgSO~) and evaporated to
dryness to give a residue which was recrystallized from
acetone-chloroform to give 1-(2-carboxyethyl)tetrazole-5-
thiol, m.p. 158-160.
- 25 -

'
To a solution of 4.18 g. (0.01 mol.) of 7-(2- ~
thienylacetamido)cephalosporanic acid sodium salt in 50 ml.
of water was added 2.51 g. (0.015 mol.) of 1-(2-carboxyethyl)-
tetrazole-5-thiol and 1.26 g. (0.015 mol.) of sodium bicar-
bonate. Additional amounts of sodium bicarbonate were added
to bring the pH of the reaction mixture to 7.0 and the mixture
was heated at 69 for five hours. The reaction mixture was
cooled, acidified to pH 6.0 by addition of dilute hydrochloric
acid and extracted with ethyl acetate. The aqueous phase was
acidified to pH 2.0, extracted with ethyl acetate and the
extract was evaporated to dryness to give a residue which was
chromatographed on silica with 90:10:3 chloroform-methanol-
acetic acid as eluant to give the title compound.
The title compound was dissolved in ethyl acetate
and triethylamine was added to form the corresponding tri-
ethylamine salt.
24 33N7O6S3 C6H15N 0 5 H2O
Calculated: 46.43% C; 5.95% H; 15.79% N
Found: 46.51% C; 5.83% H; 14.98% N
EXAMPLE 17
7-(2-Thienylacetamido)-3-[1-(2-carbamoylethyl)tetrazol-5-
ylthiomethyl]-3-cephem-4-carboxylic acid
When an equivalent amount of 1-(2-carboxyethyl)-
tetrazole-5-thiol was substituted in the procedure of Example
15 for 1-carboxymethyltetrazole-5-thiol, 1-(2 carbamoylethyl)-
; tetrazole-5-thiol was ob-tained, m.p. 181--]82 (dec.).
~ solution of 1-(2-carbamoylethyl)tetrazole-5-thiol
(10.4 g., 0.06 mol.) in 120 ml. of acetone was added to a
warm (45) solution of 10.9 g. (0.04 mol.) of 7-aminocephalo-
sporanic acid in a mixture of 220 ml. of water, 50 ml. oE
acetone and 8.4 g. (0.01 mol.) of sodium bicarbonate. The
:'
- 26 -
,

-
~6
temperature was raised to 65 and the pH maintained at 7.4-
~7.6 by addition of aqueous sodium carbonate solution. After
three hours, the reaction mixture was cooled to 10 and adjusted
to pH 3.5 by addition of dilute hydrochloric acid. The re-
sulting solid was collected by filtration, washed with water
and acetone and suspended in 95 ml. of 1.5N hydrochloric acid.
The acid suspension was stirred at 25 for five hours, filtered
and the pH of the filtrate was adjusted to 3.5 by addition of
solid sodium bicarbonate. The solid was collected by filtra-
tion and washed with water and acetone to give 7-amino-3-[1-(2
carbamoylethyl)tetrazol-5-ylthiomethyl-]-3-cephem-4-carboxylic
acid.
7-Amino-3-[l-(2-carbamoylethyl)tetrazol-5-ylthio-
methyl]-3-cephem-4-carboxylic acid and 2-thiophene acetyl
chloride were reacted according to the procedure of Example 13
to give the title compound.
The title compound was dissolved in methanol and
sodium methoxide solution was added until pH 6.9. Evaporation
of the methanol gave the title compound as its sodium salt.
18 18N7O5S3 Na 0.5 H2O
Calculated: 39.99% C; 3.54% H; 18.13% N
Found: 39.92% C; 3.48% H; 17.60% N
7-(2-Thienyl)-3-[l-(2-carbamoylethyl)tetrazol-5-yl-
thiomethyl]-3-cephem~4-carboxylic acid sodium salt is converted
to the title compound by methods previously described.
EXAMPLE 18
7-(1-Tetrazolylacetamido)-3-(1-carboxymethylte-trazol-5-
ylthiomethyl)-3 cephem-4-carboxylic aci_
7-(1-Tetrazolylacetamido)cephalosporanic acid (1.41
g., 3.7 mmol.) and 0.96 g. (6.0 ~nol.) of l-carboxymethyltetra-
zole-5-thiol were added to a solution of 0.815 g. (9.7 mmol.)
- 27 -
. . .
.
,
.

%~
of sodium bicarbonate in 25 ml. of water. An additional 0.5`04
g. (6.0 mmol.~ of sodium bicarbonate was added to bring the pH
to 6.7 and the reaction mixture was heated at 63 for five
hours while maintaining the pH at 6.6-6.8 by addition of acetic
acid. The mixture was cooled, acidified to pH 1.9 by addition
of 3N hydrochloric acid and extracted with ethyl acetate. The
extract was dried (Na2SO4) and evaporated to dryness. The
residue was dissolved in ethyl acetate and ether and hexane
- were added to precipitate the title compound.
C14EIl~Nl0o6s2 0.6 C4 8 2
Calculated: 36.79% C; 3.53% H; 26.16% N
Found: 36.28% C; 3.50% H; 25.85% N
EXAr~PLE 19
7-(1-Tetrazolylacetamido)-3-[1 (2-carboxyethyl)tetrazol-
_ylthiomethyl]-3-cephem-4-carboxylic acid
When an equivalent amount of 1-(2-carboxyethyl)-
tetrazole-5-thiol was substituted in the procedure of Example
` 18 in place of 1-carboxymethyltetrazole-5-thiol, the title
compound was obtained.
C15H16N10O6 2
Calculated: 36.28% C; 3.24% H; 28.21% N
Found: 35.80% C; 3.67% H; 24.16% N
EXA~PLE_20
7-(1-Tetrazolylacetamido)-3-[1-(3-carboxypropyl)tetrazol
5-ylthiomethyl]-3-cephem-4-carboxyllc acid
When an equivalent amount of 4-aminobutyric acid
was substituted in the procedure of Example 16 Eor ~-alanine,
~ methyl 3-carboxypropyldithiocarbamate was prepared.
- Reaction of methyl 3-carboxypropyldithiocarbamate
with sodium azide and sodium hydroxide as described in Example
; - 28 -
'

16 gave 1-(3-carboxypropyl)tetrazole-5-thiol, m.p. 99-101.
Substitution of an equivalent amount of 1-(3-
carboxypropyl)te-trazole-5-thiol in the procedure of Example
18 in place of 1-carboxymethyltetrazole-5-thiol gave the
title compound.
6Nloo6s2 2 Na 2H2O 0.5 C3H8O
Calculated: 33.87% C; 3.89% H; 22.57% N
Found: 34.39% C; 3.46% H; 22.20% N
EXAMPLE 21
, 10 7-(2-Thienylacetamido-3-[1-(3-carbamoylpropyl)tetrazol-5-
ylthiomethyl]-3-cephem-4-carboxylic acid
When an equivalent amount of 1-(3-carboxypropyl)-
tetrazole-5-thiol was substituted in the procedure of Example
15 for 1-carboxymethyltetrazole-5-thiol, 1-(3-carbamoylpropyl)-
tetrazole-5-thiol was obtained, m.p. 133-136.
Reaction of 1-(3-carbamoylpropyl)tetrazole-5-thiol
and 7-aminocephalosporanic acid as described in the procedure
of Example 17 gives 7-amino-3-[1-(3~carbamoylpropyl)tetrazol-
5-ylthiomethyl]-3-cephem-4-carboxylic acid.
/-Amino-3-[1-(3-carbamoylpropyl)tetrazol-5-ylthio-
methyl]-3-cephem-4-carboxylic acid and 2-thiophene acetyl chloride
are reacted according to the procedure of Example 13 to give
the title compound.
EXAMPLE 22
7-(1-Tetrazolylacetamido)-3-[1-(5-carboxypentyl)tetrazol-5-
ylthiomethy]-3-cephem-4-carboxylic acid
Substitution of an equivalent amount of 6-amino-
caproic acid in the procedure of Example 16 for ~-alanine gave
methyl 5-carboxypentyldithiocarbamate.
~ 30 Reaction of methyl 5-carboxypentyldi-thiocarbamate
- with sodium azide and sodium hydroxide as described in Example
- 29 -

s~:~
16 gave 1-(5-carboxypentyl)tetrazole-5-thiol, m.p. 100-100.5.
Substitution of an equivalent amount of 1-(5- -
carboxypentyl)tetrazole-5-thiol in the procedure of Example
18 in place of 1-carboxymethyltetrazole-5-thiol gave the title
compound.
C18H22N10O6S2 0.33 CH40
Calculated: 40.09% C; 4.28% H; 25.50% N
Found: 40.29% C; 4.18% H; 25.78% N
EXAMPLE 23
7-(1-Tetrazolylacetamido)-3-rl-(5-carbamoylpentyl)tetrazol
5-ylthiomethyl]-3-cephem-4-carboxylic acid
1-(5-Carboxypentyl)tetrazole-5-thiol (6.0 g., 28
mmol.) was slowly dissolved in 20 ml. of thionyl chloride and
the mixture was stirred at 25 for 1.5 hours. Evaporation of
the reaction mixture to dryness gave a residue which was dis-
; solved in 30 ml. of tetrahydrofuran. The tetrahydrofuran solu-
tion was added to a cold mixture of 60 ml. of ammonium hydroxide
and 30 ml. of tetrahydrofuran and the resulting mixture was
stirred at 25 for two days. The mixture was extracted with
ethyl acetate. The aqueous phase was acidified to pH 1 by
addition of 6N hydrochloric acid to precipitate 1-(5-carbamoyl-
pentyl)tetrazole-5-thiol, m.p. 155-157.
Reaction of 7-(1-tetrazolylacetamido)cephalosporanic
acid, 1-(5-carbamoylpentyl)tetrazole-5-thiol sodium salt, pre-
pared from 1-(5-carbamoylpentyl)tetrazole-5-thiol as described
in Example 1, and sodium bicarbonate according to the procedure
- of Example 1, gives the title compound.
EXA~PLE 24
7-(2-Thienylacetamido)-3-[1-(10 carbamoyldecyl)tetrazol-5-
ylthiomethyl]-3-cephem-4-carboxylic acid
,
l-(10-Carbamoyldecyl)tetrazole-5-thiol was prepared
'
- 30 -
,

25'~
from 1-(10-carboxydecyl)tetrazole-5-thiol by the procedure
described in Example 15, m.p. 112-114.
To a solution of 0.084 g. (1.0 mmol.) of sodium
bicarbonate in 11 ml. of water was added 0.285 g. (1.0 mmol.)
of l-(10-carhamoyldecyl)tetrazole-5-thiol. The reaction mixture
was heated to ca. 66, 0.250 g. (0.6 mmol.) of 7-(2-thienyl-
acetamido)cephalosporanic acid sodium salt was added and the
heating was continued for 5.5 hours. The reaction mixture was
chromatographed on XAD-4 resin with water as the eluant. The
product-containing fractions were evaporated to dryness and
lyophilized and the residue was chromatographed on silica with
9:1:0.5 chloroform-isopropanol-formic acid as eluant to give
the title compound.
The title compound was converted to the correspond-
ing sodium salt as previously described.
26 34 7 5 3 2
Calculated: 47.79% C; 5.36% H; 15.01% N
Found: 48.17% C; 5.37% H; 14.52% N
EXAMPLE 25
7-(1-Tetrazolylacetamido)-3-[1-(10-carboxydecyl)tetrazol-5-
ylthiomethyl]-3-cephem-4-carboxylic ac d
A suspension of 56 g. (1.0 mol.) of potassium
hydroxide and 100 g. (0.5 mol.) of ll-aminoundecanoic acid
in 170 ml. of water was stirred for 30 minutes at 25 then
40 g. (0.52 mol.) of carbon disulfide and 80 ml. of ethanol
were added and the reaction mixture was stirred at 25 for
12 hours. The mixture was refluxed gently for two hours and
; cooled. Methyl iodide (71 g., 0.3 mol.) and 130 ml. of
ethanol were added to the mixture and it was stirred at 25
, 30 for 12 hours. The mixture was evaporated to remove the ethanol
and the solid residue was collected by filtration to yive
; me-thyl 10-carboxydecyldithiocarbamate potassium salt.
-31-
.
.

!~ .
; Methyl 10-carboxydecyldithiocarbamate (28 g., 0.096
mol.), obtained from the potassium salt as described above,
was reacted with 6.5 g. ~0.1 mol.) of sodium azide according
to the procedure described in Example 16. Acidification upon
work-up gave l-(10-carboxydecyl)tetrazole-5-thiol as a white
precipitate, m.p. 95-98.
l-(10-Carboxydecyl)tetrazole-5-thiol, 7-(1-tetrazolyl-
acetamido)cephalosporanic acid sodium salt and sodium bicarbonate
were reacted as described in Example 24 to give the title com-
pound.
EXAMPLE 26
7-(1-Tetrazolylacetamido)-3-[1-(2-carboxy-1-methylethyl)-
tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid
... .. ... _ .
Substitution of an equivalent amount of 3-aminobutyric
acid in the procedure of Example 16 for ~-alanine gave methyl
(2-carboxy-1-methyl)ethyldithiocarbamate.
Treatment of methyl (2~carboxy-1-methyl)ethyldithio-
carbamate with sodium azide also as described in Example 16
gave 1-(2-carboxy-1-methylethyl)tetrazole-5-thiol, m.p. 169-
172.
7-(1-Tetrazolylacetamido)cephalosporanic acid and
1-(2-carboxy-1-methylethyl)tetrazole-5-thiol are reacted in the
presence of excess sodium bicarbonate as described in Example
16 to give the title compound.
EXAMPLE 27
When an equivalent amount of an amino acid listed be-
low:
alanine
2-aminobutyric acid
2-aminovaleric acid
2-aminohexanoic acid
,
- - 32 -

~ 3
is used in the procedure of Example 16 in place of ~-alanine
and the resulting dithiocarbamates are treated with sodium
azide as described therein, the following substituted tetrazole
thiols are obtained:
l-(l-carboxyethyl)tetrazole-5-thiol
l-(l-carboxypropyl)tetrazole-5-thiol
l-(l-carboxybutyl)tetrazole-5-thiol
l-(l-carboxypentyl)tetrazole-5-thiol
Reaction of a tetrazole thiol listed above wlth
7-(1-tetrazolylacetamido)cephalosporanic acid as described
hereinabove gives the following compounds of this invention:
7-(1-tetrazolylacetamido)-3-[1-(1-carboxyethyl)-
tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid
7-(1-tetrazolylacetamido)-3-[1-(1-carboxypropyl)-
tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid
7-(1-tetrazolylacetamido)-3-[1-(1-carboxybutyl)-
tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid
7-(1-tetrazolylacetamido)-3-[1-(1-carboxypentyl)-
tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid.
Likewise, reaction of a substituted tetrazole thiol
listed a~ove with 7-(2-thienylacetamido)cephalosporanic acid
according to theprocedures described herein gives the corres-
ponding 7--(2--thienylacetamido)-3-(1-carboxyalkylte-trazol-5-
ylthiomethyl)-3-cephem-4-carboxylic acids.
EXAMPLE 28
The following compounds were prepared according -to
procedures described hereinabove:
7--(2-thienylacetamido)-3-[1-(3-carboxypropyl)tetrazol-
i 5-ylthiomethyl]~3-cephem-4-carboxylic acid
lgH18N6S3O6 2 Na 2 H2O
Calculated: 37.75% C; 3.67% H; 13.89% N
Found: 38.25% C; 3.61% H; 13.49% N

^--~
:
~ 5'-~
7~(2-thienylacetamido-3-[1-(5-carboxypentyl)-
tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid
21H22N66S3 2 Na 0.75 H2O
Calculated: 41.34% C; 3.88% H; 13.77% N
Found: 41.30% C; 3.76% H; 13.58% N
EXAMPLE 29
An injectable pharmaceutical composition is formed by
adding sterile water or sterile saline solution (2 ml.) to
500 mg. of 7-(2-thienylacetamido)-3-~1-(2-carbamoylethyl)-
; 10 tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid, sodium
salt.
Pharmaceutical compositions of the other antibacterial
compounds disclosed above may be form~lated in a similar manner.
.~
`-
:`
~ .
:
- 34 -
,:

Representative Drawing

Sorry, the representative drawing for patent document number 1072543 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: IPC from MCD 2006-03-11
Inactive: Expired (old Act Patent) latest possible expiry date 1997-02-26
Grant by Issuance 1980-02-26

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
None
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column (Temporarily unavailable). To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.

({010=All Documents, 020=As Filed, 030=As Open to Public Inspection, 040=At Issuance, 050=Examination, 060=Incoming Correspondence, 070=Miscellaneous, 080=Outgoing Correspondence, 090=Payment})


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Claims 1994-03-27 6 153
Abstract 1994-03-27 1 19
Drawings 1994-03-27 1 13
Descriptions 1994-03-27 34 1,162